At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 472 enrolled
Drug / intervention
Faster-acting insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
In Brief
A Phase 3 clinical trial evaluating Faster-acting insulin aspart and insulin aspart for Diabetes and Diabetes Mellitus, Type 1. Completed, enrolled 472 participants across 92 sites in 9 countries.
Detailed Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 1
CountriesBelgium, Canada, France, Germany, Netherlands, Russia, Slovenia, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedJul 2016
Primary CompletionJun 2017
Study CompletionJul 2017
TodayJul 2026
First PostedJul 7, 2016
Enrollment StartJul 6, 2016
Primary CompletionJun 20, 2017
Study CompletionJul 21, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.0 years ago
Interventions
Faster-acting insulin aspartdrug
Injected s.c. /subcutaneously (under the skin)
insulin aspartdrug
Injected s.c. /subcutaneously (under the skin)